About Laminar Pharma
Laminar Pharma is a company based in Palma (Spain) founded in 2006.. Laminar Pharma has raised $14.71 million across 5 funding rounds from investors including European Union, Fundación Alba Pérez and Dentol Capital. Laminar Pharma offers products and services including LAM561, LAM226, and LAM204. Laminar Pharma operates in a competitive market with competitors including Jazz Pharmaceuticals, Merck, Roivant Sciences, Gilead and Lilly, among others.
- Headquarter Palma, Spain
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Laminar Pharmaceuticals S.A.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$14.71 M (USD)
in 5 rounds
-
Latest Funding Round
$6.27 M (USD), Series A
Jul 19, 2024
-
Investors
European Union
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Laminar Pharma
Laminar Pharma offers a comprehensive portfolio of products and services, including LAM561, LAM226, and LAM204. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Drug for glioblastoma treatment in clinical trials
Molecule targeting specific diseases like cancers
Innovative compound for unmet medical needs
Unlock access to complete
Funding Insights of Laminar Pharma
Laminar Pharma has successfully raised a total of $14.71M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $6.27 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series A — $6.3M
-
First Round
First Round
(01 Dec 2017)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2024 | Amount | Series A - Laminar Pharma | Valuation | Fundacionalbaperez , Matutes family | |
| Oct, 2023 | Amount | Series A - Laminar Pharma | Valuation |
investors |
|
| Nov, 2022 | Amount | Grant - Laminar Pharma | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Laminar Pharma
Laminar Pharma has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, Fundación Alba Pérez and Dentol Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Funds are raised by Fundación Alba Pérez for childhood cancer research.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Laminar Pharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Laminar Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Laminar Pharma Comparisons
Competitors of Laminar Pharma
Laminar Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Merck, Roivant Sciences, Gilead and Lilly, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| domain | founded_year | HQ Location |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| domain | founded_year | HQ Location |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Laminar Pharma
Frequently Asked Questions about Laminar Pharma
When was Laminar Pharma founded?
Laminar Pharma was founded in 2006 and raised its 1st funding round 11 years after it was founded.
Where is Laminar Pharma located?
Laminar Pharma is headquartered in Palma, Spain. It is registered at Palma, Balearic Islands, Spain.
Is Laminar Pharma a funded company?
Laminar Pharma is a funded company, having raised a total of $14.71M across 5 funding rounds to date. The company's 1st funding round was a Grant of $280.53K, raised on Dec 01, 2017.
What does Laminar Pharma do?
Developer of melipathy based drugs. The company provides various products such as LAM561 anticancer drug acting through cell membrane modification, LAM226 Omega-3 lipid derivative which specifically targets neuronal membranes for Alzheimers, LAM204 polyunsaturated fatty acid to replace steroid anti-inflammatory treatments and LAM30171 fatty acid derivative as a potential treatment for cancer and metabolic disorders.
Who are the top competitors of Laminar Pharma?
Laminar Pharma's top competitors include Merck, Roivant Sciences and Jazz Pharmaceuticals.
What products or services does Laminar Pharma offer?
Laminar Pharma offers LAM561, LAM226, and LAM204.
Who are Laminar Pharma's investors?
Laminar Pharma has 4 investors. Key investors include European Union, Fundación Alba Pérez, Dentol Capital, and Matutes family.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.